These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 17846812

  • 1. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
    Maia CR, Matte BC, Ludwig HT, Rohde LA.
    Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB, Gupta S, Heverin E, Starr HL.
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [Abstract] [Full Text] [Related]

  • 3. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [Abstract] [Full Text] [Related]

  • 4. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M, Bukstein O, Pechansky F.
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [Abstract] [Full Text] [Related]

  • 5. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 7. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 14. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, Liu HJ, Huang YS, Cheng H, Hsu YC, Liu SI, Pan CH, Huang YF, Huang CF, Wu YY, Huang YH, Liu HC, Chang HL.
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [Abstract] [Full Text] [Related]

  • 15. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH, Polcari A, Foley M, Valente E, McGreenery CE, Chang WW, McKay G, Midha KK.
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [Abstract] [Full Text] [Related]

  • 16. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
    Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN.
    Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
    [Abstract] [Full Text] [Related]

  • 17. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P, Kodesh A, Weizman A.
    Clin Neuropharmacol; 2017 Mar; 40(1):11-15. PubMed ID: 27879551
    [Abstract] [Full Text] [Related]

  • 18. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Sep; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 20. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
    Gormez V, Avery B, Mann H.
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.